
CAS 1193383-09-3
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
6 produits concernés.
1H-Pyrazole-4-carboxylic acid, 1-[6-chloro-5-(trifluoromethoxy)-1H-benzimidazol-2-yl]-
CAS :Formule :C12H6ClF3N4O3Degré de pureté :%Couleur et forme :SolidMasse moléculaire :346.64921-(6-Chloro-5-(Trifluoromethoxy)-1H-Benzo[D]Imidazol-2-Yl)-1H-Pyrazole-4-Carboxylic Acid
CAS :1-(6-Chloro-5-(Trifluoromethoxy)-1H-Benzo[D]Imidazol-2-Yl)-1H-Pyrazole-4-Carboxylic AcidDegré de pureté :98+%Masse moléculaire :346.65g/molJNJ-42041935
CAS :JNJ-42041935 (HIF-PHD Inhibitor II) is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.Formule :C12H6ClF3N4O3Degré de pureté :99.58% - ≥95%Couleur et forme :SolidMasse moléculaire :346.65JNJ 42041935
CAS :Produit contrôlé<p>Applications JNJ 42041935 is a selective hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) enzyme inhibitor. It can potentially be used for the treatment of inflammation-induced anemia.<br>References Barrett, T., et al.: Mol. Pharmacol., 79, 910 (2011); Thirstrup, K., et al.: Pharmacol. Res., 64, 268 (2011);<br></p>Formule :C12H6ClF3N4O3Couleur et forme :NeatMasse moléculaire :346.65JNJ 42041935
CAS :<p>JNJ 42041935 is a pharmacologic agent that inhibits the growth of cancer cells and may be used to treat chronic kidney disease. This drug binds to the extracellular matrix, which prevents the proliferation of cells in the tissue. JNJ 42041935 has been shown to inhibit the production of messenger RNA in urine samples taken from patients with chronic kidney disease. The clinical studies have shown that JNJ 42041935 can reduce the incidence of leukemia and blood disorders. The effective dose for this drug is not yet known, but it is thought that it may be around 1-10 mg/kg daily. It is also unknown how long JNJ 42041935 will remain in the body or what its excretion rate is.</p>Formule :C12H6ClF3N4O3Degré de pureté :Min. 95%Masse moléculaire :346.65 g/mol




